Sensei Biotherapeutics Inc (SNSE) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Sensei Biotherapeutics Inc   (NASDAQ: SNSE)


Sensei Biotherapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Sensei Biotherapeutics Inc 's ROA in the second quarter of 2026?
Sensei Biotherapeutics Inc recorded a cumulative net loss of $-196 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -175.68%.

However, within the Healthcare sector 832 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4536, from total ROA ranking in the first quarter of 2026 at 4802.

What is ROA?



Return On Assets (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 496.9 % 436.62 % -49.51 % -48.19 % -46.96 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -196 -184 -21 -24 -27
Return On Assets (TTM) -175.68 % -256.56 % -70 % -67.55 % -63.64 %
SNSE's Total Ranking # 4536 # 4802 # 4187 # 4220 # 4259
Total Assets (TTM) in million 189 205 23 28 32
Seq. Total Assets Change -7.83 % 796.78 % -16.99 % -13.01 % -17.13 %
Seq. Net Income Change - - - - -



Return On Assets Company Ranking
Within: No.
Industry # 394
Sector # 833
Overall # 4402

Return On Assets Statistics
High Average Low
-22.41 %
-61.92 %
-256.5 %
(Dec 31 2021)   (Mar 31 2026)





Financial Statements
Sensei Biotherapeutics Inc 's Assets $ 189 million SNSE's Balance sheet
Sensei Biotherapeutics Inc 's Income $ -16 million Quarterly SNSE's Income Statement
SNSE's Income by Division See SNSE's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025
(Dec 31 2024)
FY 2024
(Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
Y / Y Total Assets Change -49.51 % -39.01 % -37.17 % -22.74 % -
Total Assets in million 23 45 74 118 153
Y / Y Net Income Change - - - - -
Net Income in million -21 -30 -34 -49 -37
Annual Return On Assets -92.07 % -66.48 % -45.85 % -41.05 % -24.01 %




More Return On Assets Ratios
SNSE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SNSE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SNSE's Competitors
Subscribers only: Roa for Sensei Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Assets for SNSE's Customers

You may also want to know
SNSE's Roi SNSE's Inventory Turnover Ratio SNSE's Growth Rates SNSE's Dividend Comparisons
SNSE's Profitability Ratios SNSE's Asset Turnover Ratio SNSE's Dividend Growth
SNSE's Roe SNSE's Valuation Ratios SNSE's Financial Strength Ratios SNSE's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA


Date modified: 2026-08-31T19:36:52+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.